Sun Pharmaceutical Industries Ltd. sees a credit rating action

Yes. Both rating assessments explicitly incorporate transaction funding, including a cash component, but they differ in the level of disclosure.

• CRISIL: It estimates Sun Pharma’s net debt-to-EBITDA at 1.5–2.0x in FY2028, the first full year after completion. The assessment assumes USD 2.0–2.5 billion of cash surplus and internal accruals are deployed toward the acquisition, with the balance funded through USD 9.5–10.0 billion of additional debt. Thus, the projected leverage already reflects the transaction-related cash outflow, not merely the debt assumed or raised. ^[1]
• ICRA: It projects post-acquisition leverage of approximately 1.5x net debt-to-OPBDITA in FY2028, declining to around 0.5x by FY2030 as combined-business cash flows are used for deleveraging. ICRA’s metric is OPBDITA rather than CRISIL’s EBITDA, so the ratios are directionally comparable but not perfectly identical. ^[2]

What is explicitly factored in

The funding structure is central to the calculations:

• The Organon transaction is an all-cash acquisition with an enterprise value of USD 11.75 billion and is expected to be funded through a mix of debt and Sun Pharma’s surplus liquidity. ^[3]
• ICRA says Sun Pharma had a USD 3.4 billion net cash surplus as of 30 June 2026, and that a large part of this liquidity is expected to be consumed to part-fund the acquisition. It also includes Organon’s existing debt of approximately USD 8.6 billion in the post-deal leverage assessment. ^{[4] [4]}
• CRISIL expects combined annual cash accruals of Rs 22,000–25,000 Crores after the acquisition, supporting debt service, working capital, capex and subsequent deleveraging. ^[5]

Analytical read: the agencies are not modelling the acquisition as a simple addition of Organon’s operating EBITDA against assumed debt. They incorporate both the cash depletion and the debt-funded portion. The near-term leverage step-up to roughly 1.5–2.0x reflects the loss of part of Sun Pharma’s net-cash buffer, Organon’s existing debt and incremental acquisition financing; the subsequent fall in leverage reflects expected cash generation and debt repayment.

The headline consideration is USD 11.75 billion enterprise value in an all-cash transaction; the separately disclosed equity value is USD 3.99 billion. Therefore, USD 3.99 billion should not be treated as the total transaction value. ^[3]

Organon revenue mix versus Sun Pharma’s existing base

Organon reported USD 6.2 billion of CY2025 revenue. Its disclosed mix was approximately 60% established brands, 27% innovative women’s-health medicines and 13% biosimilars. ^[6]

\*Implied from USD 6.2 billion multiplied by the disclosed category percentages.

Sun Pharma’s closest disclosed proxy for “Specialty” is its innovative portfolio, comprising 29 globally marketed products and contributing approximately 22% of FY2026 revenue. Applying that share to FY2026 consolidated revenue of Rs 58,462 Crores gives an implied base of approximately Rs 12,862 Crores; this is a derived proxy, not a separately reported Specialty-segment revenue figure. ^{[7] [8]}

Analytical read: Organon is not merely adding a small specialty product tranche. Its women’s-health innovative products alone represent 27% of Organon’s revenue, while biosimilars add another 13%; together, those two categories account for roughly 40% of Organon revenue, or about USD 2.48 billion derived. ^[6] However, the comparison with Sun’s Emerging Markets segment cannot be made precisely because an absolute Emerging Markets revenue base is not provided in the cited disclosure. Sun reports Emerging Markets as a separate business category, but only the domestic and US revenue shares are quantified there. ^[9]

The figures above are Organon’s standalone revenue mix, not incremental post-closing Sun Pharma revenue; the transaction remained subject to regulatory approvals and was expected to close in late 2026 or early 2027. ^[3]*